Skip to content
    Clinical Trials

    Proton beam therapy yields high local control in nonmetastatic HCC, registry finds

    Chuong et alAdvances in radiation oncology

    Proton beam therapy yields high local control in nonmetastatic HCC, registry finds
    Findings from the multi-institutional Proton Collaborative Group REG001-09 prospective registry study (NCT01255748) evaluate treatment outcomes and toxicity for definitive proton beam therapy (PBT) in nonmetastatic hepatocellular carcinoma (HCC) across 9 United States institutions.
    The study included 88 patients treated between 2013 and 2021. Median age was 68 years (range, 40–91), and 85.0% had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Median tumor size was 4.7 cm (range, 1.2–19 cm). Baseline hepatic function was Child-Pugh class A in 43 patients (71.7%) and class B in 15 patients (25.0%). PBT was administered predominantly using moderate hypofractionation, with a median prescribed total dose of 59.1 Gy(RBE) across a median of 15 fractions (range, 5–33 fractions) and a median prescribed biologically effective dose (BED10) of 86.4 Gy(RBE) (range, 48.7–144 Gy[RBE]).
    At a median follow-up of 25.1 months (range, 17.5–36.8 months), estimated 2-year clinical endpoints were: • Freedom from local failure (FFLF): 93.4% (95% CI, 86.0%–100.0%) • Freedom from intrahepatic failure (FFIF): 67.3% (95% CI, 54.2%–80.4%) • Freedom from distant failure (FFDF): 91.8% (95% CI, 83.9%–99.7%) • Progression-free survival (PFS): 38.4% (95% CI, 26.5%–50.2%) • Overall survival (OS): 54.9% (95% CI, 42.4%–67.4%)
    On multivariable analysis, no clinical or treatment factors were significantly associated with overall survival. Regarding safety, no grade 3 or higher toxicities were reported. These multi-institutional findings confirm that dose-escalated PBT achieves high local control with a favorable toxicity profile in Western HCC cohorts.

    Key Takeaways

    • In patients with nonmetastatic hepatocellular carcinoma treated with definitive proton beam therapy, the estimated 2-year freedom from local failure rate was 93.4% (95% CI, 86.0%–100.0%) and the 2-year overall survival rate was 54.9% (95% CI, 42.4%–67.4%).
    • Proton beam therapy demonstrated high tolerability with no reported grade 3 or higher toxicities across the multi-institutional cohort.
    • Estimated 2-year freedom from intrahepatic failure, freedom from distant failure, and progression-free survival rates were 67.3% (95% CI, 54.2%–80.4%), 91.8% (95% CI, 83.9%–99.7%), and 38.4% (95% CI, 26.5%–50.2%), respectively.
    Read the original sourceAdvances in radiation oncology